Announcements Trials
Browse Landscape

Phase

Phase 3 7Phase 2 6Phase 1 5Phase 1/2 4Phase 2/3 2Phase 4 1

Status

Completed 30Terminated 10Recruiting 5Active not recruiting 5Withdrawn 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 4Thoracic 1

Conditions

Multiple Myeloma 4Neoplasms, Plasma Cell 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 118pembrolizumab 104Specimen Handling 104Magnetic Resonance Spectroscopy 94fludarabine 92Biopsy 77Injections 53Nivolumab 43Bevacizumab 41Fluorouracil 38venetoclax 37Cisplatin 36Paclitaxel 35Carboplatin 35Cetuximab 34Radiotherapy 31Oxaliplatin 30fludarabine phosphate 29Leucovorin 28Gemcitabine 28Drug Therapy 25Ipilimumab 23Immunotherapy, Adoptive 23Azacitidine 23Radiation 21Irinotecan 21Temozolomide 20Doxorubicin 20tislelizumab 19atezolizumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × carfilzomib × Clear all
NCT06622005 2026-04-21

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Roswell Park Cancer Institute

Phase 1 Recruiting
15 enrolled
Plasma cell

Multiple Myeloma

NCT06249282 2026-04-03

Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer

City of Hope Medical Center

Phase 1 Recruiting
15 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03909412 2026-02-18

CarMob

Hackensack Meridian Health

Phase 1 Recruiting
18 enrolled
Plasma cell

Multiple Myeloma

NCT05651932 2026-02-10

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

K36 Therapeutics, Inc.

Phase 1 Recruiting
125 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05137054 2026-01-22

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Regeneron Pharmaceuticals

Phase 1 Recruiting
317 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡